TG Therapeutics, Inc.
TGTX
$48.74
$0.801.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 76.08% | 81.26% | 87.32% | 100.88% | 30.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 76.08% | 81.26% | 87.32% | 100.88% | 30.96% |
| Cost of Revenue | 138.00% | 144.28% | 161.70% | 152.01% | 135.86% |
| Gross Profit | 66.80% | 72.19% | 77.47% | 94.11% | 22.77% |
| SG&A Expenses | 58.67% | 58.73% | 50.38% | 42.16% | 36.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.11% | 68.68% | 71.72% | 61.75% | 50.37% |
| Operating Income | 58.80% | 149.91% | 194.13% | 20,452.28% | -15.71% |
| Income Before Tax | 53.68% | 192.97% | 319.59% | 731.98% | -30.98% |
| Income Tax Expenses | -6,114.71% | -13,212.39% | -15,468.11% | -75,198.75% | 6,109.89% |
| Earnings from Continuing Operations | 630.24% | 1,079.81% | 1,812.41% | 3,215.24% | -36.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 630.24% | 1,079.81% | 1,812.41% | 3,215.24% | -36.82% |
| EBIT | 58.80% | 149.91% | 194.13% | 20,452.28% | -15.71% |
| EBITDA | 58.87% | 149.85% | 193.79% | 25,302.45% | -15.80% |
| EPS Basic | 634.72% | 1,080.17% | 1,803.34% | 3,184.55% | -38.32% |
| Normalized Basic EPS | 70.13% | 216.38% | 319.08% | 724.42% | -32.61% |
| EPS Diluted | 641.10% | 1,092.91% | 1,928.26% | 2,540.56% | -37.96% |
| Normalized Diluted EPS | 69.43% | 214.64% | 334.69% | 626.01% | -31.90% |
| Average Basic Shares Outstanding | -1.57% | -0.38% | 0.09% | 0.85% | 1.19% |
| Average Diluted Shares Outstanding | -1.33% | -0.03% | 3.05% | 6.09% | 6.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |